Aranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:
- Myocardial infarction, or heart attack, as well as congestive heart failure
Hypertension (high blood pressure), with increased risk of stroke
- Venous thromboembolism
- Thrombosis of vascular access
- Tumor progression or recurrence
If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
Happy Veterans Day 2019
“Honoring the sacrifices many have made for our country in the name of freedom and democracy i…Read More 08 Nov 2019, Friday
Deficiency Judgment and Foreclosures
A person borrowing money to buy a home assumes the loan is secured by the mortgage lien on the house…Read More 07 Nov 2019, Thursday
How Can a Lawyer Help You Defend Against Foreclosure?
If you fall behind on your mortgage payments, your house might end up in foreclosure. However, there…Read More 21 Oct 2019, Monday